Unexpectedly, IFN-α treatment suppressed the growth of B16/OVA and B16/OVA-JAK1−/− cell-derived tumors (Figures 6A,B), suggesting that type I IFN signaling in the host contributes to the anti-tumor efficacy of IFN-α4. The gene discussed is IFNA4; the disease is neoplasm.